DIA: Driving Insights to Action
Science:Life Sciences
“As biosimilars receive FDA approval and more and more become available to patients, we're beginning to see a greater understanding and appreciation for these medicines as lower cost options,” explains Dr. Hillel Cohen, executive director of scientific affairs in the Sandoz division of Novartis and Sandoz representative to the education committee of the US Biosimilars Council. “You are not being switched to a new medication. You're being kept on the same medication that's being made by a different manufacturer.”
DARWIN EU: Evolution in Europe’s Use of Big Data
Master Protocol Efficiencies Speeding COVID-19 Treatments
Found in Translation: A Tumultuous Year in Review
R2D2 Aligning Regulatory and HTA Review to Quicken Patient Access
Jump In, Be Brave, Have the Conversation – Reducing Health Disparities among Minority Patients
CTD Speeding Medicines Registration in East Africa
Biosimilar Savings and Their Price: BPCIA Turns Ten
Regulators Promote Reliance as 21st Century Best Practice
Regulatory and Clinical Science Align to Fight COVID-19
DIA Keynote Calls for Expanded COVID-19 Trial Parameters
Impact Philanthropy Accelerating Cures Within Reach
FDA Guidance: Flexibility But No Compromise on Patient Safety
Digital Tools Powering More and Safer Clinical Trials
Latin America's COVID-19 Regulatory Response
Partnerships Essential to SAHPRA Pandemic Response
EFPIA Shares Industry View of EMA Regulatory Framework
Time to Press the Pause Button on Speedy Drug Approvals?
Reach More Patients While Improving Data Quality?
ATMPs May Deliver on Promise of Individualized Medicine
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Speaking of Psychology
Stuff To Blow Your Mind